Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713760 | PMC |
| http://dx.doi.org/10.1007/s00406-023-01712-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effects of risk preferences on consumers' reference-dependent choices for autonomous vehicles.
Risk Anal
December 2024
University of Liverpool Management School, University of Liverpool, Liverpool, UK.
Advances in artificial intelligence (AI) are reshaping mobility through autonomous vehicles (AVs), which may introduce risks such as technical malfunctions, cybersecurity threats, and ethical dilemmas in decision-making. Despite these complexities, the influence of consumers' risk preferences on AV acceptance remains poorly understood. This study explores how individuals' risk preferences affect their choices among private AVs (PAVs), shared AVs (SAVs), and private conventional vehicles (PCVs).
View Article and Find Full Text PDFSociety of Family Planning Clinical Recommendation: Medication management for early pregnancy loss.
Contraception
December 2024
Planned Parenthood South Atlantic, Raleigh, NC, USA and McLeod Regional Medical Center, Florence, SC, USA; University of Washington Department of Obstetrics and Gynecology, 1959 NE Pacific St, Box 356460, Seattle, WA 98005, USA; Pegasus Health Justice Center, Dallas, TX, 75207, USA; Washington University, St. Louis, MO, USA.
Early pregnancy loss (EPL), also known as miscarriage or spontaneous abortion, makes up 15-20% of all clinically recognized pregnancies. EPL is a broad term that includes intrauterine pregnancies (IUPs) with findings that suggest the pregnancy may not progress or definitely will not progress; pregnancies with a gestational sac (GS) in the lower endometrial cavity or endocervical canal in the process of expulsion; residual pregnancy tissue or persistent GS; and complete passage of the GS without residual tissue. This document addresses medication management of EPL in which the complete passage of the GS has not yet occurred, including pregnancies concerning for and diagnostic of EPL (sometimes called "missed abortion") and EPL in progress.
View Article and Find Full Text PDFLong-Term Oncological Outcomes of Active Surveillance for Low-Risk Prostate Cancer Diagnosed During the MRI Era.
Fr J Urol
December 2024
Department of Urology, Univ. Lille, Lille, France. Electronic address:
Background: Active surveillance (AS) is the recommended approach for managing Grade-Group1 (GG1) prostate cancer (PCa). Incorporating MRI at entry improve patient selection and outcomes.
Objective: To evaluate long-term oncological outcomes of patients receiving AS selected with MRI at entry.
Exploring the Decision Making of Women When Planning an Induction of Labor: A Multi-Method Design.
Nurs Health Sci
December 2024
School of Nursing and Midwifery, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
The aim of this study was to explore women's preferences and experiences of degree of control in decision making when planning an induction of labor (IOL). This multi-method study was conducted using semi-structured individual interviews and the completion of two Control Preferences Scales by eight postnatal women from a metropolitan health service in Melbourne, Australia. Four themes were generated from the interview data: "shared decision making"; "changing expectations"; "IOL experience"; and "informed consent.
View Article and Find Full Text PDFEfficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Cancer Treat Rev
December 2024
SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low metastatic breast cancer (MBC). However, no direct comparison between the two exists, nor with the more recent datopotamab-deruxtecan (Dato-DXd).
Methods: We conducted a network meta-analysis (NMA) to compare efficacy and safety of T-DXd and SG in CT-pretreated HR+ and TN/HER2-low MBC and assess their benefit over standard CT, exploring also a comparison with Dato-DXd.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!